 Drug Costs
"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
| Descriptor ID |
D016527
|
| MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
| Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in this website by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 2 | 3 | | 2006 | 1 | 2 | 3 | | 2008 | 1 | 5 | 6 | | 2009 | 0 | 2 | 2 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 4 | 5 | | 2013 | 0 | 2 | 2 | | 2014 | 3 | 2 | 5 | | 2015 | 0 | 2 | 2 | | 2016 | 3 | 4 | 7 | | 2017 | 4 | 0 | 4 | | 2018 | 0 | 4 | 4 | | 2019 | 3 | 1 | 4 | | 2020 | 4 | 1 | 5 | | 2021 | 3 | 1 | 4 | | 2023 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles.
-
DiStefano MJ, Levy JF, Odouard IC, Anderson GF. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations. Value Health. 2023 11; 26(11):1618-1624.
-
Anderson KE, DiStefano MJ, Liu A, Mattingly TJ, Socal MP, Anderson GF. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs. Value Health. 2023 09; 26(9):1381-1388.
-
Owsley KM, Bradley CJ. Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program. Health Aff (Millwood). 2023 06; 42(6):785-794.
-
Gibbons JB, Laber M, Bennett CL. Humira: the first $20 billion drug. Am J Manag Care. 2023 02; 29(2):78-80.
-
Alvarez E, Nair KV, Tan H, Rathi K, Gabler NB, Maiese EM, Deshpande C, Shao Q. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. J Med Econ. 2023 Jan-Dec; 26(1):494-502.
-
Anderson KE, Polsky D, Dy S, Sen AP. Prescribing of low- versus high-cost Part B drugs in Medicare Advantage and traditional Medicare. Health Serv Res. 2022 06; 57(3):537-547.
-
Simon ST, Kini V, Levy AE, Ho PM. Medication adherence in cardiovascular medicine. BMJ. 2021 08 11; 374:n1493.
-
Goel V, Moran B, Kaizer AM, Sivanesan E, Patwardhan AM, Ibrahim M, DeWeerth JC, Shannon C, Shankar H. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study. Anesth Analg. 2021 06 01; 132(6):1748-1755.
-
de Havenon A, Delic A, Dehoney S, Whetman P, Sheibani N, Callaghan B, Ney J, Esper GJ, Magliocco B, Nair KV. Five-Year Trends in Payments for Neurologist-Prescribed Drugs in Medicare Part D. Neurology. 2021 04 20; 96(16):e2132-e2137.
-
Dickert NW, Mitchell AR, Venechuk GE, Matlock DD, Moore MA, Morris AA, Pierce KJ, Speight CD, Allen LA. Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost. Circ Cardiovasc Qual Outcomes. 2020 12; 13(12):e007070.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|